Publications & Posters
- Poster
Melanoma patients with multi-Siglec ligands as profiled by HYDRA technology are refractory to PD1 blockade
American Association for Cancer Research Annual Meeting, April 10, 2021, Poster #491
- Poster
HYDRA Platform Development to Investigate Siglec-engaging Tumor Immunosuppressive Glyco-codes
Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting, November 9, 2019, Abstract #P118
- Poster
Blockade of Siglec/Sialoglycan Axis Using EAGLE Technology to Potentiate Anticancer Immunity
Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting, November 8, 2019, Abstract #P273
- Publication
Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment
Cancer Immunology Research. April 23, 2019.
- Poster
A Novel Therapeutic Modality of Inhibiting the Glyco-Immune Checkpoint Axis to Treat Cancer
American Association for Cancer Research, April 2019, Poster #LB-109
- Poster
A Novel Immunomodulatory Strategy of Targeting Glyco-Immune Checkpoints with EAGLE Technology
American Association for Cancer Research, November 2018
- Poster
Targeting Tumor Sialylation in Combination with Checkpoint Inhibitors for Cancer Immunotherapy
Society for Immunotherapy of Cancer, November 2018, Poster #676
- Poster
A Novel Immunomodulatory Strategy of Targeting Glyco-Immune Checkpoints with EAGLE Technology
Society for Immunotherapy of Cancer, November 2018, Poster #037
- Publication
Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells
Journal of Clinical Investigation. August 21, 2018.
